Open AccessIntranasal Drug Delivery: Novel Delivery Route for Management of Parkinson’s and Depression Neurological Disorders
Author(s) -
Rekha Hondadakatti,
Harshada Khandelwal,
Anil Keshav Pawar,
Gajanan Sanap,
Sachin D. Shinde,
Sim T,
Rikin Patel,
Shri Bhakt
Publication year - 2021
Publication title -
letters in applied nanobioscience
Language(s) - English
Resource type - Journals
ISSN - 2284-6808
DOI - 10.33263/lianbs113.36403651
Subject(s) - nasal administration , medicine , drug delivery , drug delivery to the brain , drug , depression (economics) , nasal cavity , pharmacology , blood–brain barrier , central nervous system , surgery , nanotechnology , materials science , economics , macroeconomics
Neurological disorders are increasing worldwide due to the rapidly aging population, which increases healthcare costs. Drug delivery to the brain is challenging because of the brain's anatomy, and orally administered drugsare mostly unable to cross BBB. Intranasal (Nose to Brain) administration of drugs is one novel approach to address this challenge. Intranasal delivery has appeared to evade the blood-brain barrier (BBB) and deliver the drug into the CNS at a higher rate and degree than another traditional route. Transport of drugs from the nasal cavity to the brain along with olfactory and trigeminal nerves. The purpose of this review is drug delivery by the intranasal route for treating neurological disorders like Parkinson’s and depression because drug delivery by other routes is unable to cross BBB. Still, delivery through the intranasal route by using the nanotechnology approach is possible to deliver the drug directly to CNS.